University Hospitals (UH), a US-based academic medical centre and community hospital network, has selected insulin management software provider Glytec to enhance diabetes management.  

This alliance aims to improve care quality, cost of care, and patient experience in diabetes care.  

As part of the collaboration, Glytec’s insulin management software, Glucommander, will be first implemented at UH Cleveland Medical Center, providing healthcare professionals with tools for insulin management. 

Glytec’s platform, developed leveraging more than 100 patents as well as 100 whitepapers and medical publications, utilises evidence-based algorithms combined with real-time data analysis to offer personalised insulin dosing to patients.  

Glytec said that UH chief clinical transformation officer Dr Peter Pronovost and Dr Betul Hatipoglu, UH vice chair for UH System Clinical Affairs & Medical Director for UH Diabetes and Metabolic Center, have been key figures in establishing this alliance. 

Both have played an integral role in supporting the healthcare transformation and integrating technologies, such as Glytec’s Glucommander solution, to optimise patient care processes.  

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Pronovost said: “We are very excited for this partnership and eager to implement the Glytec solution to positively impact patient outcomes, experience, and quality of care in our journey toward Zero Harm.” 

Glytec chief medical officer Dr Jordan Messler said: “Dr Pronovost’s leadership and commitment to improving patient safety sparked my interest in quality improvement. His work nationally and at his institution aligns perfectly with Glytec’s mission to make insulin therapy safer and more effective.” 

Glytec’s software-as-a-service platform, currently deployed by more than 350 hospitals, is designed to facilitate collaborative diabetes management, improve patient outcomes, shorten hospital stays, and enhance workflow efficiency.  

The company’s FDA-cleared Glucommander cloud-based insulin management solution offers clinical decision support, identification of at-risk patients, workflow alerts, patient monitoring, and AI-powered analytics.